The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia

NANot yet recruitingINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
FibromyalgiaPregabalinDuloxetinePain
Interventions
DRUG

Pregabalin

In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.

DRUG

Pregabalin with toludesvenlafaxine

In the pregabalin with toludesvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Toludesvenlafaxine will be administered at 40 mg daily initially. If the initial dose is well-tolerated, the dose could be further escalated by 40 mg per day after 7 days, up to a maximum of 160 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and toludesvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.

Trial Locations (1)

Unknown

Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT07208357 - The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | Biotech Hunter | Biotech Hunter